Missfresh Limited(MF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MF Missfresh Limited

Delisted 12-20 16:00:00 EST

1.00

+0.00

0.00%

High1.00	Low1.00	Vol0.00
Open1.00	D1 Closing1.00	Amplitude0.00%
Mkt Cap7.77M	Tradable Cap5.59M	Total Shares7.77M
T/O0.00	T/O Rate0.00%	Tradable Shares5.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MF","market":"US","secType":"STK","nameCN":"Missfresh Limited","latestPrice":1,"timestamp":1734728400000,"preClose":1,"halted":4,"volume":0,"delay":0,"floatShares":5586728,"shares":7772983,"eps":-28.707302,"marketStatus":"Delisted","change":0,"latestTime":"12-20 16:00:00 EST","open":1,"high":1,"low":1,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-28.707302,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":90,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":1,"volumeRatio":0},"requestUrl":"/m/hq/s/MF/wiki","defaultTab":"wiki","newsList":[{"id":"2490884017","title":"Is Geron Corporation (GERN) the Best NASDAQ Penny Stock to Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490884017","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490884017?lang=en_us&edition=fundamental","pubTime":"2024-12-11 15:15","pubTimestamp":1733901319,"startTime":"0","endTime":"0","summary":"We recently published a list of 11 Best NASDAQ Penny Stocks To Buy Right Now. In this article, we are going to look at whereGeron Corporation  stands against other best NASDAQ penny stocks to buy right now.The NASDAQ Stock Market is home to some of the world’s largest companies in the world and also hosts several hundred penny stocks. These companies must meet certain requirements to remain listed on the NASDAQ exchange, including the $1 per share minimum share price thresholds, revenue standards, and market capitalization thresholds. If a company fails to meet these requirements, it may receive noncompliance notifications and eventually be delisted. According to a report by Bloomberg, this year’s market rally has boosted many of the struggling stocks, helping some companies regain compliance with NASDAQ’s listing requirements.A scientist holding a vial of the cancer-fighting drug developed by the biotechnology c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UE8z81ALQ980dMHJDG..6g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/86de9186db0cafa46e5d387cfff70682","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UE8z81ALQ980dMHJDG..6g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/86de9186db0cafa46e5d387cfff70682"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-gern-best-nasdaq-071519389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","US5Y.BOND","US3Y.BOND","SQQQ","BK4215","TQQQ","US10Y.BOND","BK4563","BK4113","LU2210149790.SGD","BK4526","US12M.BOND","LU2210150020.SGD",".IXIC","BK4139","BK4585","US30Y.BOND","LU2095319765.USD","US6M.BOND","US2Y.BOND","MAA","BK4539","US7Y.BOND","NDAQ","IE00B3QW5Z07.USD","MF","QID","BK4112","PSQ","GERN","IE00BKPKM429.USD","QLD","MNQmain","IE00B64PRP62.GBP","BK4588","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2490894048","title":"Positive Clinical Updates and Promising Therapeutic Potential for Elritercept in MDS and MF: A Strong Case for Continued Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2490894048","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490894048?lang=en_us&edition=fundamental","pubTime":"2024-12-11 00:05","pubTimestamp":1733846746,"startTime":"0","endTime":"0","summary":"Wedbush analyst Yun Zhong has maintained their bullish stance on KROS stock, giving a Buy rating yesterday. Yun Zhong’s rating is based on promisin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-clinical-updates-and-promising-therapeutic-potential-for-elritercept-in-mds-and-mf-a-strong-case-for-continued-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-clinical-updates-and-promising-therapeutic-potential-for-elritercept-in-mds-and-mf-a-strong-case-for-continued-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4563","KROS","BK4113","MF","BK4526"],"gpt_icon":0},{"id":"2490176110","title":"Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490176110","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490176110?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:00","pubTimestamp":1733839200,"startTime":"0","endTime":"0","summary":"In the dose escalation Part 1 of the study, no dose-limiting toxicities were observed and the PK profiles were similar to those reported for previous monotherapy studies of imetelstat and ruxolitinib. Based on the safety profile, imetelstat 9.4 mg/kg dosed every four weeks with ruxolitinib was the selected dose for the dose expansion Part 2 of the study, which is currently enrolling patients. \"Upon diagnosis, intermediate-1 and -2 and high-risk myelofibrosis patients typically receive ruxolitinib as the primary therapy, which reduces enlarged spleens and alleviates symptoms. These early results showing the tolerability of ruxolitinib combined with imetelstat in this patient population are highly encouraging, because as a non-JAK inhibitor treatment option with a potentially novel mechanism of action, imetelstat could provide an additive benefit, affecting the underlying malignant clones implicated in MF progression, when combined with ruxolitinib alone,\" said John Mascarenhas, M.D., Pr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pWJZ1mBrontFIBsPmSBvIQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/552cac5071faa71fd5f09cac7f030e72","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pWJZ1mBrontFIBsPmSBvIQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/552cac5071faa71fd5f09cac7f030e72"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-announces-phase-1-findings-140000504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HR","LU2463526074.USD","BK4203","MF","BK4109","BK4139","ASH","BK4539","BK4526","PK","BK4113","BK4218","BK4225","BK4563","GERN","TSS","BK4181"],"gpt_icon":0},{"id":"2490051521","title":"Clinical trial data for MF candidate proves promising for Syntara","url":"https://stock-news.laohu8.com/highlight/detail?id=2490051521","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490051521?lang=en_us&edition=fundamental","pubTime":"2024-12-10 13:08","pubTimestamp":1733807280,"startTime":"0","endTime":"0","summary":"Syntara Ltd  has reported interim data from a trial to assess the efficacy of its drug candidate for treatment of myelofibrosis , with results showing that the candidate – SNT-5505 – showed strong tolerability and improvements in both spleen volume and symptoms of the condition over time.The data – to be presented at the 66th American Society of Hematology annual meeting  – was from Syntara’s Phase 2 clinical trial for the drug, which was tested in combination with ruxolitinib .It showed a 50% improvement in Total Symptom Score  among 46% of evaluable patients following 12 weeks of treatment, with this rising to an 80% improvement at 38 weeks of treatment.TSS50 is a standard efficacy endpoint used as the primary endpoint in clinical trials related to MF.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/clinical-trial-data-for-mf-candidate-proves-promising-for-syntara-2024-12-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["MF","ASH","SRV","BK7057","BK4109","BK4539","BK4563","BK7133","LU2463526074.USD","SNT.AU","BK7164","BK4113","BK4526","BK7096","SRV.AU","ASH.AU"],"gpt_icon":0},{"id":"2490380550","title":"Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2490380550","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490380550?lang=en_us&edition=fundamental","pubTime":"2024-12-10 08:30","pubTimestamp":1733790600,"startTime":"0","endTime":"0","summary":"Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 wee","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994148/0/en/Keros-Therapeutics-Presents-Clinical-Data-from-its-Elritercept-Program-at-the-66th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MF","BK4117","BK4139","BK4539","BK4563","BK4113","LENZ","BK4526","AFG","BK4107"],"gpt_icon":0},{"id":"2490707899","title":"Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2490707899","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490707899?lang=en_us&edition=fundamental","pubTime":"2024-12-10 02:14","pubTimestamp":1733768040,"startTime":"0","endTime":"0","summary":"Incyte INCY announced positive results from the late-stage study on retifanlimab.The phase III POD1UM-304 study is evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer  not harboring a driver mutation.The POD1UM-304 study met the primary endpoint of overall survival  and all secondary endpoints in patients with previously untreated metastatic NSCLC.Shares of Incyte have risen 20.9% year to date against the industry’s 7.5% decline.Results from the POD1UM-304 study showed a clinically meaningful and statistically significant improvement over chemotherapy alone.Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis , including primary MF, post-polycythemia vera MF and post-essential throm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incytes-stage-nsclc-study-meets-181400811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GSK.UK","INCY","BK4139","OS","BK4097","LU1829250122.USD","GSK","BK4539","BK4526","BK4550","BK4563","CSTL","BK4505","IMCR","MF","BK4588","BK4113","BK4007","BK4532","BK4196","BK4585"],"gpt_icon":0},{"id":"2490083397","title":"Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490083397","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490083397?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993966/0/en/Disc-Medicine-Presents-Positive-Clinical-and-Translational-Data-Across-Portfolio-at-the-66th-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4563","IRON","BK4139","BK4539","AFG","ASH","BK4582","BK4117","EPP","BK4107","BK4113","MF","BK4526","DSS","BK4087","BK4109","IBD"],"gpt_icon":0},{"id":"2490713101","title":"Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490713101","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490713101?lang=en_us&edition=fundamental","pubTime":"2024-12-09 14:00","pubTimestamp":1733724000,"startTime":"0","endTime":"0","summary":"Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas. Innate Pharma SA   today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma  treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology  Annual Meeting in San Diego, California.The TELLOMAK study addresses a critical unmet need for patients with advanced-stage CTCL, particularly Sézary syndrome  and mycosis fungoides , who often experience debilitating symptoms such as severe itching and recurrent skin infections that profoundly impact their physical and social well-being.Patient Profile: Median age of 69, advanced disease , and a median of five prior systemic therapies, high score of pruritus  and severe Skindex-29 score  at","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/S3d2z6.8Hd_WflLKKLjigw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/646921f25dc14927fb658297457f5944","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/S3d2z6.8Hd_WflLKKLjigw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/646921f25dc14927fb658297457f5944"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innate-pharma-presents-lacutamab-improved-060000716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4109","BK4113","LU2463526074.USD","IPHA","BK4563","ASH","MF","BK4526","BK4231","BK4080","BK4139","IPHYF","ADC","BK4539"],"gpt_icon":0},{"id":"2490643077","title":"Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490643077","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490643077?lang=en_us&edition=fundamental","pubTime":"2024-12-09 09:00","pubTimestamp":1733706000,"startTime":"0","endTime":"0","summary":"Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study in MF anemia has been initiated, en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993429/0/en/Disc-Medicine-Presents-Positive-Updated-Results-from-Phase-1b-Trial-in-Patients-with-Myelofibrosis-MF-and-Anemia-in-an-Oral-Presentation-at-the-66th-American-Society-of-Hematology-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4109","LU2463526074.USD","AFG","MF","BK4139","BK4107","AE","BK4563","BK4117","BK4138","IRON","ASH","BK4526","BK4113"],"gpt_icon":0},{"id":"2489406427","title":"Generali Interested in Small U.S. Asset Managers, Milano Finanza Says, Citing Sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2489406427","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489406427?lang=en_us&edition=fundamental","pubTime":"2024-12-06 17:22","pubTimestamp":1733476920,"startTime":"0","endTime":"0","summary":"--Italian insurer Generali is considering two or three small U.S. asset managers as takeover targets, MF-Milano Finanza reports, citing unnamed sources.--Generali is evaluating businesses that are smaller than Conning, the U.S. investment manager whose acquisition it completed in April, according to MF . New York-based Mgg Investment Group was named as one of the potential targets.-- Woody Bradford, who leads the Generali Investments,  is personally involved in the process, MF reports.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MF","BK4526","BK4563","BK4113","BK4539"],"gpt_icon":0},{"id":"2489566274","title":"BRIEF-Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489566274","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489566274?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:11","pubTimestamp":1733404317,"startTime":"0","endTime":"0","summary":"Dec 5 (Reuters) - Ryvu Therapeutics SA   :   * RYVU THERAPEUTICS ANNOUNCES DOSING OF THE FIRST PATIENT IN THE POTAMI-61 PHASE II STUDY OF RVU120 FOR THE TREATMENT OF PATIENTS WITH MYELOFIBROSIS (MF)Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MF","BK4563","BK4113","BK4539","BK4139","BK4526","LENZ"],"gpt_icon":0},{"id":"2488916961","title":"Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2488916961","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488916961?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:00","pubTimestamp":1733227200,"startTime":"0","endTime":"0","summary":"Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis. Takeda to receive exclusive global license in all territories outside of mainland China, Hong Kong and Macau. Transaction builds upon Takeda’s legacy in the treatment of hematologic cancers and advances company’s global oncology strategy. OSAKA, Japan & CAMBRIDGE, Mass., December 03, 2024----Takeda  today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc.  to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.\"We are excited to partner with Takeda, whose global reach and expertise in oncology and hematology will help unlock elritercept’s potential for patients with MDS and MF,\" said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer at Keros Therapeutics. \"With a differenti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Mtrw27NZWWLQ31pFftNF8Q--~B/aD0yNjY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ab83e63c40e11825b14fac38a19f4ad0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Mtrw27NZWWLQ31pFftNF8Q--~B/aD0yNjY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ab83e63c40e11825b14fac38a19f4ad0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/takeda-strengthens-oncology-pipeline-elritercept-120000571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MF","BK4007","BK4139","BK4539","BK4526","BK4113","LENZ","TAK","BK4563"],"gpt_icon":0},{"id":"2486593558","title":"The ASX-listed Biotech set to unlock significant value","url":"https://stock-news.laohu8.com/highlight/detail?id=2486593558","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486593558?lang=en_us&edition=fundamental","pubTime":"2024-11-27 07:50","pubTimestamp":1732665047,"startTime":"0","endTime":"0","summary":"Syntara is not your typical ASX-listed biotech. This small company with a market cap of just ~A$60 million is equipped with a world class in-house drug discovery engine that has produced five lead candidates for disease with high unmet need with a shareholder base of mostly institutional investors including Australian and US specialist healthcare funds.Focused on rare and underserved diseases like myelofibrosis , Syntara is advancing three promising compounds into Phase 2 clinical trials, supported largely by non-dilutive funding. With an estimated ~US$3 billion market opportunity for MF in the U.S. alone, key clinical milestones on the horizon, a highly differentiated product pipeline, a potential accelerated path to market, and with comparable acquisitions in MF indicating ~50x upside from current levels, Syntara is positioned as a biotech company with significant upside potential and one to watch closely.Syntara has now been listed for 23-years on the ASX. At KP Rx we focus on ident","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-asx-listed-biotech-set-to-unlock-significant-value","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-asx-listed-biotech-set-to-unlock-significant-value","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4539","ASH.AU","ASH","TSS","BK7504","BK7095","BK4526","BMT.AU","BK4113","BK4563","BK7094","LU2463526074.USD","BK4109","BK4093","AML.AU","BK4588","MF","BK4585","CF","BK7057"],"gpt_icon":0},{"id":"2486058302","title":"The Magnificent Seven have seen persistent selling from active funds – Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2486058302","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486058302?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:34","pubTimestamp":1732556080,"startTime":"0","endTime":"0","summary":"5./15 WEST Most “Magnificent Seven” stocks have seen selling from active ETFs, mutual funds and hedge funds due to profit taking, concentration, and risk management, according to Citi Research. Accord","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1142745464/image_1142745464.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1142745464/image_1142745464.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4330984-the-magnificent-seven-have-seen-persistent-selling-from-active-funds-citi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["3NVD.UK","NVDD","GOOGL","LU1670711123.USD","LU0157215616.USD","LU2242649171.HKD","NVDY","00201","NVDA","SG9999001424.SGD","LU0472753341.HKD","LU1720051108.HKD","LU0784385170.HKD","LU2264538146.SGD","NVDX","FDN","LU0426417589.USD","MSFT","NVDU","BK4598","NVD3.UK","TSLA","MF","LU2298321311.HKD","LU2362541273.HKD","LU1935042488.USD","SNVD.UK","SG9999004303.SGD","LU1803068623.USD","LU0823434740.USD","LU0320765489.SGD","LU2602419157.SGD","NVD","SG9999015952.SGD","LU1699723380.USD","LU0006306889.USD","NVD2.UK","NVDS.UK","IE00B3SWFQ91.USD","LU0353189763.USD","LU0784383803.USD","LU1323610961.USD","GOOG","2NVD.UK","MAGS","NVDS","META","AAPL"],"gpt_icon":1},{"id":"2486035021","title":"Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2486035021","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486035021?lang=en_us&edition=fundamental","pubTime":"2024-11-25 23:09","pubTimestamp":1732547340,"startTime":"0","endTime":"0","summary":"- Twenty presentations, including late-breaking, oral and poster presentations, highlight advances across seven of the company’s medicines. - Late-breaking data presentation at ASH will feature results from the Phase 3 inMIND study evaluating tafasitamab in follicular lymphoma ; data to be highlighted during ASH press program. - Incyte to host virtual analyst and investor event on Thursday, December 12, 2024, from 4:00-5:00 p.m. ET to discuss key data presentations from ASH. WILMINGTON, Del., November 25, 2024----Incyte  today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology  Annual Meeting in San Diego.\"These data illustrate our innovative approach that aims to identify new and best-in-class treatments for patients with a range of cancers,\" said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. \"At ASH, we’re presenting comprehensive data from our Phase 3 inMIND trial in relapse","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5ZUY50nE6iPM_4VCQp6r7Q--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/da7813c24b8a5b0fd0f19158d36c9b59","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5ZUY50nE6iPM_4VCQp6r7Q--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/da7813c24b8a5b0fd0f19158d36c9b59"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-spotlight-data-including-breaking-150900864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","FL","BK4539","LU2463526074.USD","BK4113","MF","PT","ASH","BK4532","BK4166","BK4563","INCY","BK4094","BK4109","BK4550","BK4526","BK4588","BK4139","BTC"],"gpt_icon":0},{"id":"2484903667","title":"Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903667","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903667?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:54","pubTimestamp":1732042440,"startTime":"0","endTime":"0","summary":"Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2  in chronic spontaneous urticaria .Consequently, shares of Incyte were down 9% on Nov. 18 in after-market trading.Shares of Incyte have risen 5.4% year to date against the industry’s 11.1% decline.Incyte announced that it will pause enrollment in the ongoing phase II study of MRGPRX2 in CSU due to certain in vivo preclinical toxicology findings.The data was also shared with the FDA. The company is now working closely with the FDA to determine the next steps.Additionally, data from the phase II study evaluating MRGPRX4 in cholestatic pruritus does not support further development.IMCR’s earnings beat estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 25.57%.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-pauses-enrollment-chronic-spontaneous-185400622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","GSK","BK4113","BK4532","BK4139","BK4550","BK4196","BK4563","IMCR","BK4007","BK4526","GSK.UK","BK4505","INCY","MF","BK4585","BK4588","LU1829250122.USD","CSTL"],"gpt_icon":0},{"id":"2484940880","title":"Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2484940880","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484940880?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:59","pubTimestamp":1732017540,"startTime":"0","endTime":"0","summary":"Data from more than 20 programs, including new research from cell therapy and targeted protein degradation platforms, showcase the depth and breadth of BMS’ diverse portfolio and ongoing leadership in blood diseases and beyond. \"Our data at ASH reflect our unique ability to address unmet patient needs with our industry-leading cell therapy portfolio and the continued expansion of our work in targeted protein degradation. These advances have been built on decades of specialized research and experience across clinical development and dedication to patient-centric treatment approaches,\" said Anne Kerber, senior vice president, head of late clinical development, Hematology, Oncology, and Cell Therapy , Bristol Myers Squibb. \"This meeting provides us with an opportunity to reinforce our commitment to this critical area of research and highlight our current efforts to transform how hematologic diseases are treated.\". Key data being presented by Bristol Myers Squibb and its partners at the 20","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WciYhZEcAWBnkvf3tYO0bA--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/029df730ac198ba09da8f7f492d3b342","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WciYhZEcAWBnkvf3tYO0bA--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/029df730ac198ba09da8f7f492d3b342"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-presentations-ash-115900984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HOCT","IE00BSNM7G36.USD","LU1032466523.USD","MF","BK4207","IE0009355771.USD","LU2360032135.SGD","LU0321505439.SGD","RS","FL","BK4086","PST","MAS","LU1291159041.SGD","LU2242646821.SGD","RR","DBP","RBC","BORT","LU0640476718.USD","LU1074936037.SGD","OS","LU1280957306.USD","ASH","TD","LU0237698245.USD","LU0306807586.USD","LU0985481810.HKD","BK4566","BK4006","MYE","BK4526","BK4559","SOC","LU0321505868.SGD","BMY","LU0320765646.SGD","BK4532","CRS","RTX","PFS","CAR","CRBN","GRO","LU1718418525.SGD","LU1929549753.HKD","LU0456855351.SGD","BK4230","LU1093756325.SGD","HSCT"],"gpt_icon":0},{"id":"2482770925","title":"Press Release: Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482770925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482770925?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"-- Completed a successful end of Phase 2 meeting with the FDA for bitopertin. in erythropoietic protoporphyria , reaching alignment on all. proposed study parameters with the potential for accelerated approval. -- Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in. anemia at the American Society of Nephrology  Kidney Week 2024. \"This is an exciting time for Disc as we have made significant progress in advancing our pipeline in recent months and remain keenly focused on execution as we prepare for multiple upcoming catalysts. We now have clarity on the path forward for bitopertin in EPP, with the potential for accelerated approval, and added to the data set supporting the potential of DISC-0974 in treating anemias of inflammation with positive SAD data in NDD-CKD,\" said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. \"Additionally, with the recent completion of a debt financing with Hercules Capital, we have further solidified our strong financ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LU2463526074.USD","IBD","ASH","BK4089","BK4113","BK4526","BK4563","IRON","MF","TSAT","BK4109","EPP","BK4139","BK4582"],"gpt_icon":0},{"id":"2481108335","title":"Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481108335","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481108335?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:30","pubTimestamp":1731072600,"startTime":"0","endTime":"0","summary":"-- Facility significantly increases future financial and operational. -- Up to $200M available, with $30 million drawn at close and additional $80. million available at Disc's sole discretion through second-half 2026. recently announced potential accelerated approval pathway for bitopertin. \"Hercules is pleased to partner with Disc in the further development of their hematology pipeline,\" said Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital. \"We are committed to financing promising life sciences companies to help them achieve their ambitious goals, and we are excited to collaborate with the Disc team ahead of numerous milestones and support them in their next phase of growth.\". The loan facility consists of up to four tranches, three of which can be drawn at Disc's option and each maturing in November 2029. The loan facility provides for at least 48-months of interest-only at close, which interest-only period can be extended up to 60 months upon satisfaction of","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","IRON","BK4539","BK4582","EPP","BK4139","BK4563","HTGC","BK4113","MF","BK4526"],"gpt_icon":0},{"id":"2481903507","title":"Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481903507","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481903507?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980800,"startTime":"0","endTime":"0","summary":"Achieved $28.2 million in RYTELO  net product revenue in first full quarter of sales. Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt. FOSTER CITY, Calif., November 07, 2024----Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlights.Strong execution in the first full quarter of U.S. launch, with net product revenue for RYTELO  of $28.2 million in the third quarter of 2024.New data to be presented at upcoming American Society for Hematology  Annua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zZLo_DXqApn6_1miYjGswg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/42a99b4bc39a17084482402aa4c47f6e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zZLo_DXqApn6_1miYjGswg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/42a99b4bc39a17084482402aa4c47f6e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-reports-third-quarter-120000278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4113","BK4563","ASH","GERN","LU2463526074.USD","BK4526","MF","BK4585","BK4087","CHMP","BK4139","BK4539","BK4215","BK4109","BK4588","OS","MAA","BK4097"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Missfresh is rebuilding neighborhood retail from the ground up in China with our innovative technology and business model. We invented the DMW model by building and operating DMWs in May 2015, before any other player in on-demand DMW retail industry, according to iResearch. Through the convenient locations of our DMWs and technology-enabled DMW management, we operate an online-and-offline integrated on-demand retail business offering fresh produce and fast-moving consumer goods (FMCGs), which share the characteristics of high-frequency purchases with regular and universal demand. We strive to make grocery shopping more delightful, more efficient, more affordable and more trustworthy. To that end, we operated a technology-enabled network of 631 DMWs in 16 cities in China as of March 31, 2021. We have also built up a full stack of proprietary technology to empower participants in the neighborhood retail business such as supermarkets, fresh markets and local retailers with our core capabilities.","exchange":"NASDAQ","name":"Missfresh Limited","nameEN":"Missfresh Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Missfresh Limited(MF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Missfresh Limited(MF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Missfresh Limited,MF,Missfresh Limited股票,Missfresh Limited股票老虎,Missfresh Limited股票老虎国际,Missfresh Limited行情,Missfresh Limited股票行情,Missfresh Limited股价,Missfresh Limited股市,Missfresh Limited股票价格,Missfresh Limited股票交易,Missfresh Limited股票购买,Missfresh Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Missfresh Limited(MF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Missfresh Limited(MF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction